Studies on the Metabolic Fate of Amrubicin Hydrochloride (SM-5887), a Novel Antitumor Agent. (I): Blood Concentration, Distribution, Metabolism and Excretion after a Single Intravenous Administration to Rats.
Shunji NAKAI(Sumitomo Chemical (Japan)), Shinichi Ninomiya(Kai Research (United States)), Setsuko Komuro(Sumitomo Chemical (Japan)), Shinobu GUNJI(Kai Research (United States)), Atsushi TAKAO(Kai Research (United States)), Masao Ishizaki(Kai Research (United States)), Iwao Nakatsuka(Sumitomo Chemical (Japan)), Yoshiko Mizuno(Development Bank of Japan), Kyoko AKAO(Sumitomo Chemical (Japan)), Hiroshi Kanamaru(Sumitomo Chemical (Japan)), Tomoko NAKAYAMA(Kai Research (United States)), Kazue Kimura(Kai Research (United States)), Yoshio ESUMI(Kai Research (United States)), Masaki Ito(Sumitomo Chemical (Japan))
Cited by 1
Related Papers
Associations of medical status and physical fitness with periodontal disease
|Journal Of Clinical Periodontology|1999|164
Inflammation and the Development of Atherosclerosis
|Journal of Atherosclerosis and Thrombosis|2011|163
Prevalence of adult patients with congenital heart disease in Japan
|International Journal of Cardiology|2009|134